Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Purilax is a series of cross-linked hyaluronic acid (HA) dermal fillers developed by WEDERM Global for aesthetic procedures. Utilizing high-purity HA, the product is designed to restore facial volume, contour features, and smooth moderate-to-severe wrinkles and folds. The filler works by integrating into the dermal tissue, where the HA molecules bind water to create a volumizing effect and provide structural support. The cross-linking technology ensures the gel's stability and longevity within the tissue, allowing for sustained aesthetic improvement. It is typically administered via injection into the mid-to-deep dermis or subcutaneous layers depending on the specific product variant and treatment area.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Purilax.